http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 10 Jul 2026 21:56:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jul+08++Filed+by%3A+HANNAH+ALISON+L./26758313.html si-local-file:///var/storage/secattach/20260710/26758313.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jul+08++Filed+by%3A+HANNAH+ALISON+L./26758313.html Fri, 10 Jul 2026 21:56:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jul+08++Filed+by%3A+HANNAH+ALISON+L./26758313.html si-local-file:///var/storage/secattach/20260710/26758313.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jul+08++Filed+by%3A+HANNAH+ALISON+L./26758313.html Fri, 10 Jul 2026 21:56:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 13,375 restricted stock units to six non-executive employees vesting over four years with 25% of the grant vesting each year.</p><p><b><u>About Rigel</u></b><br />Rigel Pharmaceuticals, Inc. (Nasdaq: http://www.streetinsider.com/Press+Releases/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html Tue, 07 Jul 2026 08:05:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 13,375 restricted stock units to six non-executive employees vesting over four years with 25% of the grant vesting each year.</p><p><b><u>About Rigel</u></b><br />Rigel Pharmaceuticals, Inc. (Nasdaq: http://www.streetinsider.com/Press+Releases/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html Tue, 07 Jul 2026 08:05:00 -0400 O.00187291 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 13,375 restricted stock units to six non-executive employees vesting over four years with 25% of the grant vesting each year.</p><p><b><u>About Rigel</u></b><br />Rigel Pharmaceuticals, Inc. (Nasdaq: http://www.streetinsider.com/PRNewswire/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html Tue, 07 Jul 2026 08:05:00 -0400 O.00187291 RIGL http://www.streetinsider.com/PRNewswire/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 7, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals, Inc.</span> Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 13,375 restricted stock units to six non-executive employees vesting over four years with 25% of the grant vesting each year.</p><p><b><u>About Rigel</u></b><br />Rigel Pharmaceuticals, Inc. (Nasdaq: http://www.streetinsider.com/PRNewswire/Rigel+Pharmaceuticals%2C+Inc.+Announces+Inducement+Grants+under+NASDAQ+Listing+Rule+5635%28c%29%284%29/26738953.html Tue, 07 Jul 2026 08:05:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+25/26720759.html si-local-file:///var/storage/secattach/20260701/26720759.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+25/26720759.html Wed, 01 Jul 2026 16:12:00 -0400 O.00187291 RIGL http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+25/26720759.html si-local-file:///var/storage/secattach/20260701/26720759.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++RIGEL+PHARMACEUTICALS+++++For%3A+Jun+25/26720759.html Wed, 01 Jul 2026 16:12:00 -0400 O.00187291 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html <p>Rigel Pharmaceuticals (Nasdaq: RIGL) appointed Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, according to a company statement.</p> <p>Dr. Hannah resigned from Rigel's Board of Directors, where she had served since May 2021, in connection with her appointment. She succeeds Lisa Rojkjaer, M.D. in the role.</p> <p>Prior to joining Rigel's executive team, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc., which was acquired by Pharmacia & Upjohn and is now part of Pfizer. At SUGEN, she worked on the development of tyrosine kinase inhibitors http://www.streetinsider.com/Management+Changes/Rigel+names+former+board+member+as+chief+medical+officer/26717211.html Wed, 01 Jul 2026 08:05:19 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html <div class="xn-content"> <ul type="disc"><li><i><person>Dr. Hannah</person></i> <i>has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 </i></li><li><i>She has resigned from Rigel's Board of Directors to join the company</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of <person>Alison L. Hannah</person>, M.D. to the role of Executive Vice President and Chief Medical Officer. <person>Dr. Hannah</person> has resigned from Rigel's Board of Directors, effective <chron>July 1, 2026</chron>, in connection with http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html Wed, 01 Jul 2026 08:05:00 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html <div class="xn-content"> <ul type="disc"><li><i><person>Dr. Hannah</person></i> <i>has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 </i></li><li><i>She has resigned from Rigel's Board of Directors to join the company</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of <person>Alison L. Hannah</person>, M.D. to the role of Executive Vice President and Chief Medical Officer. <person>Dr. Hannah</person> has resigned from Rigel's Board of Directors, effective <chron>July 1, 2026</chron>, in connection with http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html Wed, 01 Jul 2026 08:05:00 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html <div class="xn-content"> <ul type="disc"><li><i><person>Dr. Hannah</person></i> <i>has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 </i></li><li><i>She has resigned from Rigel's Board of Directors to join the company</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of <person>Alison L. Hannah</person>, M.D. to the role of Executive Vice President and Chief Medical Officer. <person>Dr. Hannah</person> has resigned from Rigel's Board of Directors, effective <chron>July 1, 2026</chron>, in connection with http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html Wed, 01 Jul 2026 08:05:00 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html <div class="xn-content"> <ul type="disc"><li><i><person>Dr. Hannah</person></i> <i>has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 </i></li><li><i>She has resigned from Rigel's Board of Directors to join the company</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of <person>Alison L. Hannah</person>, M.D. to the role of Executive Vice President and Chief Medical Officer. <person>Dr. Hannah</person> has resigned from Rigel's Board of Directors, effective <chron>July 1, 2026</chron>, in connection with http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html Wed, 01 Jul 2026 08:05:00 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html <div class="xn-content"> <ul type="disc"><li><i><person>Dr. Hannah</person></i> <i>has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 </i></li><li><i>She has resigned from Rigel's Board of Directors to join the company</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of <person>Alison L. Hannah</person>, M.D. to the role of Executive Vice President and Chief Medical Officer. <person>Dr. Hannah</person> has resigned from Rigel's Board of Directors, effective <chron>July 1, 2026</chron>, in connection with http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html Wed, 01 Jul 2026 08:05:00 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html <div class="xn-content"> <ul type="disc"><li><i><person>Dr. Hannah</person></i> <i>has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 </i></li><li><i>She has resigned from Rigel's Board of Directors to join the company</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of <person>Alison L. Hannah</person>, M.D. to the role of Executive Vice President and Chief Medical Officer. <person>Dr. Hannah</person> has resigned from Rigel's Board of Directors, effective <chron>July 1, 2026</chron>, in connection with http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html Wed, 01 Jul 2026 08:05:00 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html <div class="xn-content"> <ul type="disc"><li><i><person>Dr. Hannah</person></i> <i>has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 </i></li><li><i>She has resigned from Rigel's Board of Directors to join the company</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sousco" idsrc="xmltag.org" >SOUTH SAN FRANCISCO, Calif.</location></span>, <span class="legendSpanClass"><chron>July 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:RIGL" idsrc="xmltag.org" >Rigel Pharmaceuticals</span>, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of <person>Alison L. Hannah</person>, M.D. to the role of Executive Vice President and Chief Medical Officer. <person>Dr. Hannah</person> has resigned from Rigel's Board of Directors, effective <chron>July 1, 2026</chron>, in connection with http://www.streetinsider.com/Press+Releases/Rigel+Appoints+Board+Member+Alison+L.+Hannah%2C+M.D.+as+Chief+Medical+Officer/26717210.html Wed, 01 Jul 2026 08:05:00 -0400 A.07880129 A.19465411 A.36613195 A.50207590 O.00187291 O.00530995 O.21200813 O.22422653 O.24977989 RIGL